Antimicrobial activity of doripenem against clinical bacterial pathogens from Europe, 2009
Abstract number: P1874
Farrell D., Moet G., Sader H., Putnam S., Jones R.
Objectives: To evaluate the in vitro antimicrobial activity of Doripenem (DOR) against prevalent Gram-negative and -positive pathogens isolated in Europe (EU) during 2009. DOR is an approved carbapenem in EU for the treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
Methods: A total of 5,481 consecutive, non-duplicate isolates from a wide variety of infections were collected from 24 medical centers located in Europe, Turkey, and Israel during 2009. Species identification was confirmed by the central monitoring laboratory and all isolates were susceptibility (S) tested using reference CLSI broth microdilution methods (M7-A8, 2009) against DOR and comparator agents.
Results: Doripenem was very active against Enterobacteriaceae, inhibiting 99% of isolates at 0.5 mg/L (MIC 90, 0.12 mg/L). DOR had good activity against P. aeruginosa (MIC50/90, 0.5/8 mg/L) and most Acinetobacter spp., inhibiting >70% of isolates at 8 mg/L (MIC50/90 = 2/>8 mg/L). Against Gram-positive pathogens, DOR had very high activity against methicillin-susceptible S. aureus (MSSA), MS-coagulase-negative staphylococci (CoNS), b-haemolytic streptococci, and S. pneumoniae with MIC90 values of 0.06, 0.12, 0.06, and 0.5 mg/L, respectively. DOR was less active against MRSA and MR-CoNS with both having an MIC50 of 2 mg/L, as well as E. faecalis (MIC50, 4 mg/L). DOR was not active against the vast majority of E. faecium (MIC50, >8 mg/L, range 0.25>8 mg/L).
Conclusions: DOR exhibited a wide spectrum of antimicrobial activity against 5,481 contemporary EU pathogens and excellent activity against most Gram-positive pathogens except for MRSA, MR-CoNS and Enterococci. Against Gram-negative pathogens, DOR exhibited excellent activity against Enterobacteriaceae and good activity against many multidrug resistant P. aeruginosa and Acinetobacter spp. This data supports the use of DOR as therapy for hospitalized patients, in whom carbapenem therapy would be warranted to treat serious and typically difficult-to-treat infections, such as NP, cIAI, VAP, and cUTI in Europe, Turkey and Israel.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|